Welcome and Introduction
Understanding the Rationale and Mechanism of Action for PARP Inhibition in MBC
Integrating PARP Inhibition Into Clinical Management of Patients With MBC
Future Directions in PARP Inhibitors in Breast Cancer: Where Do We Go From Here?
Final Thoughts and Audience Question and Answer Session
Mark Robson, MD
Chief, Breast Medicine Service
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Lee Schwartzberg, MD, FACP
West Cancer Center
Professor of Medicine
University of Tennessee Health Science Center
CCO User, MD
Associate Professor of Medicine
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with breast cancer.
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with metastatic breast cancer.
- Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating metastatic breast cancer
- Identify patients based on molecular changes and previous therapy that are most likely to benefit from treatments with PARP inhibitors
- Integrate single-agent PARP inhibitors into the treatment of appropriately selected patients with metastatic breast cancer
- Refer eligible patients with metastatic breast cancer to clinical trials of single-agent PARP inhibitors and combinations of PARP inhibitors with other anticancer therapies
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 2.0 contact hours.
NCCN designates this knowledge-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. UAN: JA4008196-9999-19-004-L01-P
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.